Huntington's disease is a fatal neurodegenerative disorder caused by a CAG repeat expansion encoding a polyglutamine tract in the huntingtin (Htt) protein 1 . Here we report a genome-wide overexpression suppressor screen in which we identified 317 ORFs that ameliorate the toxicity of a mutant Htt fragment in yeast and that have roles in diverse cellular processes, including mitochondrial import and copper metabolism. Two of these suppressors encode glutathione peroxidases (GPxs), which are conserved antioxidant enzymes that catalyze the reduction of hydrogen peroxide and lipid hydroperoxides 2 . Using genetic and pharmacological approaches in yeast, mammalian cells and Drosophila, we found that GPx activity robustly ameliorates Huntington's disease-relevant metrics and is more protective than other antioxidant approaches tested here. Notably, we found that GPx activity, unlike many antioxidant treatments, does not inhibit autophagy, which is an important mechanism for clearing mutant Htt. Because previous clinical trials have indicated that GPx mimetics are well tolerated in humans, this study may have important implications for treating Huntington's disease.
Genetic and chemical screens have used yeast models of Huntington's disease to isolate gene-deletion suppressors, gene-deletion enhancers and chemical modifiers of mutant Htt toxicity [3] [4] [5] [6] , thereby helping elucidate the cellular pathways that are involved in mutant Htt toxicity and identifying several promising therapeutic targets and compounds. Here we complemented this work via a systematic screen of the Yeast ORF Collection (Open Biosystems) 7 , which contains the vast majority of the fungus' ORFs (>5,500/6,607) in expression vectors maintained in the parental Y258 yeast strain. We transformed a construct encoding a mutant Htt fragment (Htt103Q), which forms aggregates and causes cellular toxicity 8 , into each ORF strain and tested them for suppression of Htt103Q-dependent toxicity using growth assays (Fig. 1a,b) .
We identified 317 ORFs that suppressed Htt103Q toxicity in yeast (Supplementary Table 1) , 172 (~54%) of which are functionally annotated in the Saccharomyces Genome Database and 39 of which have one-to-one human orthologs ( Table 1) . Analysis of the functionally annotated genes with the DAVID bioinformatics package 9 identified a number of enriched groups ( Table 2) , including mitochondrial import, copper chaperone activity and purine biosynthesis. Notably, genes encoding components of the mitochondrial protein import machinery-which is crucial for the import of nuclear-encoded proteins to the mitochondrial membranes and matrix 10 -were the largest significantly enriched group (P < 0.001) ( Table 2 and Supplementary  Fig. 1 ). Impaired mitochondrial protein import due to the amyloid beta peptide (Aβ) has been observed in Alzheimer's disease 11 , suggesting that mutant Htt may cause a similar dysfunction in yeast.
To explore functional connectivity among the suppressor ORFs, we performed network analysis using the Osprey Network Visualization System (Version 1.2.0) 12 . Osprey uses the BioGRID database 13 to build networks by inserting all known interactions for each gene of interest ('node'). The interactions (or 'edges') are derived from several sources, including affinity capture experiments and synthetic lethality analyses. Using this approach, we observed a total of 166 interactions among 111 nodes (data not shown). To select genes with higher-level relationships, we processed the network data with an iterative minimum filter of two, which identified all of the nodes with a minimum of two interactions within the group (Fig. 1c) . This analysis uncovered a highly interconnected network of 57 nodes with 115 edges, which reinforced and expanded the functionally enriched groups among the suppressors, including protein localization in mitochondria (P = 1.9 × 10 −5 ), purine ribonucleotide biosynthetic process (P = 6.4 × 10 −3 ), copper ion transport (P = 1.3 × 10 −2 ) and regulation of GTPase activity (P = 3.2 × 10 −2 ). This analysis suggests that although the suppressors fall into several functional categories, many interact in a common network.
We next compared the list of ORF suppressors that we identified here to the published modifier screens in yeast 3, 6 , which have identified 28 gene-deletion suppressors and 52 enhancers of mutant Htt toxicity. Because genes that enhance mutant Htt toxicity when deleted might be expected to suppress toxicity when overexpressed, we were surprised to find only one gene in common between the ORF overexpression suppressors and the gene-deletion enhancers (MMS4, which encodes a subunit of the Mms4-Mus81 endonuclease that is involved in DNA repair 14 ) and no overlap with the deletion suppressors. This might be explained by the earlier screens not being systematic and instead representing random screens of pooled genedeletion strains. However, this observation may also suggest that 1 2 5 0 VOLUME 45 | NUMBER 10 | OCTOBER 2013 Nature GeNetics l e t t e r s protective genes do not necessarily need to have roles in the pathways that contribute to mutant Htt toxicity.
In addition to providing mechanistic insight into the nature of mutant Htt toxicity, we previously found that genetic screens in yeast can uncover new candidate therapeutic targets for Huntington's disease 3, 15, 16 . Two of the most robust suppressors we identified are GPX1 and HYR1 (also called GPX3), which encode antioxidant GPx enzymes (Fig. 1b) . Many studies with Huntington's disease models and patient samples have indicated that oxidative stress may have an important role in disease pathogenesis 3, 17, 18 . Indeed, the amounts of oxidative stress markers are increased in the plasma of both symptomatic and pre-manifest patients with Huntington's disease 19 . We also previously observed increased amounts of reactive oxygen species (ROS) in yeast expressing Htt103Q 3 . Notably, GPX1 and HYR1 (GPX3) were the only antioxidant genes that emerged from our screen, suggesting that this class of antioxidant enzymes is particularly protective against mutant Htt toxicity. Although the overall amounts of oxidative stress are increased in patients with Huntington's disease, the total GPx activity remains unchanged in these individuals 20, 21 ; thus, supplementation of GPx activity may have therapeutic value.
We therefore investigated the efficacy of modulating GPx activity in a mammalian cell model of mutant Htt toxicity. First we expressed mouse Gpx1 (mGpx1), the most abundant mammalian GPx protein, in yeast and found that it also suppresses Htt103Q toxicity (Fig. 1b) . We then tested mGpx1 in a neuron-like rat pheochromocytoma (PC12) cell line that inducibly expresses a mutant Htt fragment (Htt103Q) 22 . Htt103Q expression in these cells results in several Huntington's disease-relevant phenotypes, including the formation of mutant Htt aggregates and increased caspase-3 activation, which is a marker of apoptosis 23 . Htt103Q expression in PC12 cells did not significantly alter GPx activity, which is analogous to the results from patients with Huntington's disease (Fig. 2a) . We found that cells stably overexpressing mGpx1 showed a ~35% increase in total cellular GPx activity (P < 0.0001; Fig. 2a ) and a ~50% reduction in caspase-3 and caspase-7 (caspase-3/7) activation in response to mutant Htt expression (P < 0.0001; Fig. 2b ). Thus, as in yeast cells, the increased expression of GPx is protective in this mammalian cell model of Huntington's disease.
The availability of small selenocysteine-containing molecules that mimic GPx make supplementation of GPx activity therapeutically viable in Huntington's disease 24 . Ebselen, the best characterized of these compounds, is highly bioavailable, readily crosses the bloodbrain barrier 25 and has produced promising results in clinical trials for stroke 24 and noise-induced hearing loss 26 . We thus tested ebselen in Huntington's disease cells and found a significant ~66% reduction of caspase-3/7 activation compared to control cells treated with vehicle (DMSO) (P < 0.0001) (Fig. 2c) .
We next examined whether this rescue of mutant Htt toxicity was due to the scavenging of ROS. To ensure that any changes in ROS amounts were unrelated to apoptosis, we assayed the cells 6 h after the induction of mutant Htt, a time point before any significant increases in caspase activation (data not shown). The amounts of ROS were 1.9-fold higher (P < 0.0001) in PC12 cells expressing Htt103Q compared to uninduced controls, and ebselen treatment (P < 0.0001) or expression of mGpx1 (P < 0.0001) markedly abrogated this increase (Fig. 2d) .
Thus, we analyzed mGpx1 in vivo by taking advantage of a widely used Huntington's disease model in Drosophila that expresses an exon-1 fragment of mutant Htt (Htt93Qex1) 27 . We drove expression of Htt93Qex1 using the UAS-GAL4 system either pan-neuronally with the elav-GAL4 driver or in circadian clock neurons using the Pdf-GAL4 driver. Expression of Htt93Qex1 with elav-GAL4 generates several disease-relevant phenotypes, including degeneration of photoreceptor neurons (rhabdomeres) in the fly eye (Fig. 3a,b) . mGpx1 overexpression resulted in ~35% neuroprotection (P < 0.001) in the eyes of 10-day-old adult flies, as well as rescue at days 1 (P < 0.05) and 7 (P < 0.001) (Fig. 3b) . Notably, we observed a significant genotype × time interaction (F 2,50 = 7.76, P = 0.0012), reflecting a slowed progression of neurodegeneration in the eye when mGPx1 l e t t e r s was coexpressed (Fig. 3b) . We found that Huntington's disease flies (elav-GAL4 driven) showed a ~57% reduction in locomotor activity compared to wild-type (w118) and mGpx1-alone controls (P < 0.001) and that overexpression of mGpx1 completely restored locomotor activity (P < 0.01) (Fig. 3c) . Furthermore, we found that expression of mGpx1 was able to ameliorate the circadian arrhythmicity generated by expression of Htt93Qex1 in neurons expressing the neuropeptide pigment-dispersing factor (Pdf) 28 , resulting in an ~1.8-fold increase in the fraction of rhythmic flies (Supplementary Table 2 ). We reasoned that this arrhythmicity was due to the neurodegeneration of the small lateral ventral neurons (s-LN v s) 28 , which are particularly important for self-sustained circadian behavioral rhythmicity in constant darkness 29 . Indeed, we observed a reduced number of s-LN v s in flies expressing Htt93Qex1 (Fig. 3d and Supplementary Fig. 2 ), whereas the large lateral ventral neurons (the other Pdf-expressing clock neurons) were not affected (data not shown) 28 . Notably, mGpx1 expression in Huntington's disease flies completely rescued the neurodegeneration of s-LN v s ( Fig. 3d and Supplementary Fig. 2 ).
To test whether pharmacological GPx activity ameliorates neurodegeneration, we transferred newly emerged adult Huntington's disease flies to vials of food containing ebselen or vehicle (DMSO). We found that ebselen was able to rescue up to ~60% of rhabdomere degeneration at day 7 (P < 0.001) (Fig. 3e) . Thus, our in vivo analyses in Drosophila provide further support for our observations in yeast and mammalian cells.
A remaining question is why GPx activity is robustly protective in these models when, in general, antioxidant strategies have had limited efficacy in Huntington's disease models and patients with Huntington's disease despite strong evidence that oxidative stress contributes to pathology 18 . As we did not identify other classical antioxidant genes in our screen, we individually tested a panel of antioxidant genes in our yeast model of Huntington's disease. We found that unlike GPx activity, the overexpression of superoxide dismutases, catalases and glutathione reductases in yeast did not consistently confer protection against Htt103Q-mediated toxicity (Supplementary Table 3) . We thus analyzed PC12 cells and found that overexpression of catalase or superoxide dismutase 1 (SOD1), although increasing enzyme activity, did not ameliorate mutant Htt-induced caspase activation (Supplementary Fig. 3a-c) . Furthermore, pan-neuronal expression of ectopic catalase in the mitochondrial matrix of fruit flies, which has been shown to substantially decrease mitochondrial hydrogen peroxide release 30 , was not neuroprotective ( Supplementary  Fig. 3d) , and past work has found that overexpression of either cytosolic or mitochondrial forms of superoxidase dismutase does not reduce neurodegeneration in a fly model of Huntington's disease 31 . Thus, we conclude that GPx activity is a particularly robust antioxidant strategy in the Huntington's disease models tested.
A possible explanation for these results comes from the observation that many antioxidants inhibit basal and induced levels of autophagy, a process that is known to be protective in several models of Huntington's disease 31 . Indeed, treatment with several antioxidants, as well as overexpression of superoxide dismutase, can enhance neurodegeneration in a Drosophila model of Huntington's disease. We thus tested whether ebselen modulated autophagy in PC12 cells through measurement of the autophagy marker LC3-II (Fig. 4a) . We found that ebselen did not alter the induction of autophagy by rapamycin, whereas a control antioxidant (N-acetylcysteine) strongly The human orthologs were determined using g:Profiler, which is a web-based tool for the functional interpretation of gene lists 44 . The annotation clusters were determined using the DAVID Functional Annotation tool. The number of genes refers to the genes within the input gene list that fell into the specified cluster. The P values represent the threshold of the EASE score, which is a modified Fisher's exact P value, for the gene-enrichment analysis. Fold enrichment is the overall enrichment of the particular cluster over background.
npg l e t t e r s inhibited the induction of autophagy (Fig. 4b) . These observations indirectly support the notion that GPx activity acts as a protective antioxidant strategy for Huntington's disease by reducing the amounts of ROS without adverse effects on autophagy.
We have shown that increasing total cellular GPx activity by genetic or pharmacological means is protective in multiple Huntington's disease model systems, probably through decreased oxidative damage. Indeed, we found that mutant Htt-dependent increases in ROS amounts can be blocked by both ebselen treatment and overexpression of mGpx1. This is in agreement with previous work showing that modulation of mGpx1 activity influences toxicity in cell-based and animal models of oxidative stress 32 . As ROS have an important role in apoptotic signaling, elevating GPx activity not only decreases apoptosis but also protects mice and primary neurons from apoptotic agents 33, 34 . Therefore, it is probable that some of the GPx protection observed in our study occurs through a similar mechanism. Though not addressed in our study, increased GPx activity also decreases neuroinflammation in response to ischemia-reperfusion 33 . Recent work supports a role for neuroinflammation in Huntington's disease pathology 35 ; thus, it is possible that GPx treatment in patients with Overexpression of mGpx1 increases total GPx activity in PC12 cells (****P < 0.0001 compared to uninduced controls; n = 7 per condition). (b) Quantification of caspase-3/7 activation in response to Htt103Q expression in cells overexpressing mGpx1. Overexpression of mGpx1 reduces Htt103Q-mediated caspase-3/7 activation (****P < 0.0001). Values represent the ratio of caspase-3/7 activity in cells expressing Htt103Q for 72 h compared to cells not expressing Htt103Q (n = 12 (WT); n = 9 (monomeric red fluorescent protein (mRFP)); n = 8 (mGpx1) per condition). (c) Effect of the GPx mimetic ebselen on Htt103Q-mediated caspase activation. A single 10 µM dose of ebselen significantly reduced caspase-3/7 activation in Htt103Q-expressing cells (****P < 0.0001). Values represent the ratio of caspase-3/7 activity in cells expressing Htt103Q for 72 h compared to cells not expressing Htt103Q. Statistical analysis was performed using an unpaired, two-tailed Mann-Whitney test (n = 12 per condition). (d) mGpx1 overexpression (****P < 0.0001) and ebselen treatment (****P < 0.0001) significantly reduce Htt103Q-mediated ROS production (n = 9 per condition). Unless stated otherwise, all statistical analyses were performed using one-way analysis of variance (ANOVA) with post-hoc tests. NS, not significant. **P < 0.01. All data are shown as the mean ± s.e.m. overexpression at days 1 (n = 14 (Htt93Q); n = 9 (Htt93Q + mGpx1)), 7 (n = 7 (Htt93Q); n = 9 (Htt93Q + mGpx1)) and 10 (n = 8 (Htt93Q); n = 9 (Htt93Q + mGpx1)) after eclosion. Significant effects of genotype (F 1,50 = 82.3, P = 3.82 × 10 −12 ) and age (F 2,50 = 94.3, P = 1.06 × 10 −17 ) were observed, as well as a significant interaction between genotype and age (F 2,50 = 7.76, P = 0.00116), indicating that mGpx1 reduces the rate of neurodegeneration in Htt93Q flies. Post-hoc Newman-Keuls comparisons showed significant rescue of neurodegeneration in mGpx1-expressing flies at days 1 (*P < 0.05), 7 (***P < 0.001) and 10 (***P < 0.001). Browne-Forsythe analyses for equality of variance revealed a significant inequality of variance (P = 0.02) due to a single group (Htt93Q + mGpx1, day 1). The nonparametric Mann-Whitney test confirmed a difference at day 1 between the two groups (P = 0.03), and between Htt93Q + mGpx1 flies at days 1 and 7 (P < 0.0001). (c) Total locomotor activity was assessed as the average number of beam crossings per 30-min bin per fly. Htt93Qex1-expressing flies (n = 29) have reduced locomotor activity compared to controls (***P < 0.001; n = 30 (WT (w118)); n = 32 (mGpx1)), which is restored by mGpx1 (**P < 0.01; n = 32). Comparisons were performed by Kruskal-Wallis one-way ANOVA. (d) Neurodegeneration of Pdf clock neurons was assessed using confocal microscopy in adult flies at day 7. Flies expressing Htt93Qex1 driven by Pdf-GAL4 (n = 16 brain hemispheres) showed loss of s-LN V s compared to Canton S (CS) control flies (n = 13), which was ameliorated by coexpression of mGpx1 (****P < 0.0001; n = 16). Comparisons were performed by Kruskal-Wallis one-way ANOVA. (e) Quantification of the average number of rhabdomeres per ommatidium in Huntington's disease flies with ebselen or vehicle (DMSO; n = 10) treatment at day 7 after eclosion and in newly emerged day 0 adult flies (untreated control; n = 10). Significant treatment effects were observed, both with the 100 µM (**P < 0.01; n = 9) and 300 µM (***P < 0.001; n = 9) doses of ebselen. All data are shown as the mean ± s.e.m.
npg l e t t e r s
Huntington's disease may have protective effects through a dampening of this inflammatory response. An important feature of our study is the availability of several efficacious GPx mimetics that are well tolerated by humans 24 . Notably, we have shown that treatment with the well-characterized GPx mimetic ebselen is strongly protective in both mammalian-cell and fly models of Huntington's disease. In addition to directly scavenging ROS 36 , ebselen is able to decrease ROS amounts by inhibiting the activity of several ROS-producing enzymes, including lipoxygeneases 37 , nitric oxide synthase 38 and NADPH oxidase 39 , which contributes to ROS production in Huntington's disease 40 . These additional modes of ROS elimination may partially explain why we found ebselen to be more neuroprotective than mGpx1 (Figs. 2 and 3) . It is important to underscore the finding that ebselen does not inhibit basal or induced autophagy in mammalian cells. As recent work has found that autophagy is regulated by ROS signaling 41 , our observations suggest that the peroxides targeted by GPx activity are not required for this regulation. In summary, our study shows that GPx mimetics may hold considerable promise for treating Huntington's disease and possibly other neurodegenerative disorders in which oxidative stress has an important role 24, 42, 43 .
MeTHOds
Methods and any associated references are available in the online version of the paper. Densitometric analysis of the bands was performed using ImageJ, and the amounts of LC3-II are expressed relative to the untreated control. All statistical analyses were performed using one-way ANOVA with post-hoc tests (****P < 0.0001). All data are shown as the mean ± s.e.m.; n = 7 per condition.
npg and 80% glycerol in PBS. Brains were then visualized on an Olympus FV1000 confocal microscope and processed with Olympus software.
Locomotor activity and circadian rhythm analyses. For locomotor activity analysis, flies with elav-driven Htt93Qex1 expression were monitored using Trikinetics DAM2 activity monitors. Thirty-two flies per genotype were individually analyzed in activity tubes for 2 d in 12-h light, 12-h dark cycles, followed by 7 d in constant darkness, during which the circadian period was determined 47 . Locomotor activity was assayed as the average number of infrared beam crossings per 30-min bin during the light and dark regime over the 2 d. Only flies surviving for at least 5 d in the activity tubes were analyzed. For circadian rhythm analyses, flies with Pdf-driven Htt93Qex1 expression were monitored as described above. The data recorded during the constant darkness period were subjected to CLEAN spectral analysis 47 using BeFly!, an in-house behavioral analysis software package 48 .
Statistical analyses. Data were analyzed by ANOVA with Newman-Keuls post-hoc tests using Statistica (StatSoft Ltd.) or Prism 6 (GraphPad Software).
When assumptions of normality and equal variances were violated (using Browne-Forsythe or D' Agostino-Pearson/Shapiro-Wilk tests, respectively), nonparametric tests were used (see the figure legends). Sample numbers were determined empirically (ref. 15 and data not shown). Relative data values were log transformed before statistical analyses. χ 2 analysis was used to assess differences in the proportions of rhythmic and arrhythmic flies among groups.
